CD4 and cancer: Moreover, IL10 released by MSDCs and TAMs favors a CD4+ Th2 response with B-cell engagement over CD4+Th1 and cytotoxic CD8+T (Tc1) responses, which are both effective cancer immunosurveillance mechanisms [69, 73].